Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19613078 | 1.00 | KDM4E (0.34) | KDM4EKMT2AFFAR3BAZ2A | |
| SCHEMBL20413690 | 0.88 | — | — | |
| SCHEMBL7392636 | 0.87 | KDM4E (0.41) | KDM4EKMT2AFFAR3 | |
| SCHEMBL30814448 | 0.86 | HTT (0.31) | — | |
| Hydrochloric Acid SCHEMBL8417833 | 0.85 | KDM4E (0.39) | KDM4EKMT2AFFAR3 | |
| SCHEMBL3296868 | 0.83 | KDM4E (0.34) | KDM4EKMT2AFFAR3 | |
| SCHEMBL855487 | 0.83 | KDM4E (0.34) | KDM4EKMT2AFFAR3 | |
| SCHEMBL4594341 | 0.83 | KDM4E (0.34) | KDM4EKMT2AFFAR3 | |
| SCHEMBL31299993 | 0.82 | — | — | |
| SCHEMBL18347951 | 0.79 | CYP1A2 (0.33) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
| CN-109526219-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-11-12 | — | — | US | disclosed |
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-10-27 | — | — | US | disclosed |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-05-26 | — | — | US | disclosed |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2019-06-27 | — | — | US | disclosed |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| CN-109526219-A | Benzsulfamide and its purposes as therapeutic agent | 泽农医药公司 | 2019-03-26 | — | — | CN | disclosed |
| WO-2008031556-A2 | 2 AMINO-PYRIMIDINE DERIVATIVES AS H4 RECEPTOR ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | UCB PHARMA, S.A. (BE) | 2008-03-20 | — | — | WO | disclosed |
| US-5576320-A | 1-heteruarylazetidines and -pyrrolidines, process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-11-19 | — | — | US | disclosed |
| US-5565474-A | 1-heteroarylazetidines and -pyrrolidines process for their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1996-10-15 | — | — | US | disclosed |
| US-5410057-A | 1-heteroarylazetidines and -pyrrolidines | SANOFI (FR) | 1995-04-25 | — | — | US | disclosed |
| EP-0591030-A2 | 1-Heteroaryl-azetidines and -pyrrolidines as 5-HT3 agonists | SANOFI (FR) | 1994-04-06 | — | — | EP | disclosed |
| US-4886810-A | ANTIBACTERIAL | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| EP-0132845-B1 | NOVEL 1,8-NAPHTHYRIDINE DERIVATIVES, AND PROCESS FOR PREPARATION THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 1988-04-13 | — | — | EP | disclosed |
| EP-0242789-A2 | Novel quinoline derivates and processes for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-10-28 | — | — | EP | disclosed |
| US-4649144-A | Antibacterial 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid derivatives | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1987-03-10 | — | — | US | disclosed |
| EP-0132845-A2 | Novel 1,8-Naphthyridine derivatives, and process for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | KDM4E 1252/4885KMT2A 2408/4885FFAR3 1248/4885 |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | KDM4E 1252/4885KMT2A 2408/4885FFAR3 1248/4885 |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | KDM4E 1252/4885KMT2A 2408/4885FFAR3 1248/4885 |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | KDM4E 1308/4885KMT2A 2494/4885FFAR3 1404/4885 |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | KDM4E 1252/4885KMT2A 2408/4885FFAR3 1248/4885 |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | KDM4E 1308/4885KMT2A 2494/4885FFAR3 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.